Alfuzosin Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 65862-249

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 65862-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Alfuzosin Fig1)

This appears to be a graph displaying the plasma concentration of Alfuzosin over time (in hours). Without additional context or further information, it is difficult to provide a more detailed description or analysis.*

FDA Label Image

Figure 2 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 1 (Alfuzosin Fig2)

The text appears to be a partial excerpt from a medical research article or report. It includes a comparison of the effectiveness of a placebo treatment versus a drug called Alfuzosin hydrochloride in reducing symptoms measured by IPSS Total Symptom Score. The mean change in symptoms over time is represented graphically in Figure 2 and the statistical significance of the results is indicated by p<0.001.*

FDA Label Image

Figure 3 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 2 (Alfuzosin Fig3)

This is a graph showing the mean change from baseline in IPSS Total Symptom Score for Trial 2, with days of treatment on the X-axis and Hycom on the Y-axis. The text at the beginning appears to be random characters and is not readable.*

FDA Label Image

Figure 4 — Mean Change From Baseline In Ipss Total Symptom Score: Trial 3 (Alfuzosin Fig4)

FDA Label Image

Figure 5 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 1 (Alfuzosin Fig5)

FDA Label Image

Figure 6 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 2 (Alfuzosin Fig6)

The text is a partial description of a figure showing the mean change from baseline in peak urine flow rate in days of treatment of a certain trial.*

FDA Label Image

Figure 7 — Mean Change From Baseline In Peak Urine Flow Rate (ml/s): Trial 3 (Alfuzosin Fig7)

The text appears to be a graph that shows the Mean Change from Baseline in Peak Urine Flow Rate (uL/s) for Trial 3 after a treatment period of 20 days. The values on the x-axis were not included in the text. Therefore, a proper description cannot be provided.*

FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablet Bottle))

This is a description of a medication named Alfuzosin Hydrochloride Extended-Release Tablets USP, which contains 10mg Alfuzosin Hydrochloride USP. The medication is distributed by Aurobindo Pharma USA, Inc. and comes in a package of 30 tablets. The usual dosage is mentioned in the package insert. The medication should be stored in a tight and light-resistant container between 20° to 25°C (68° to 77°F); with excursions permitted to 15° to 30°C (59° to 86°F). It should be kept out of reach of children and protected from light and moisture. The code TS/DRUGS/19/1993 is also mentioned. Made in India.*

FDA Label Image

Structure (Alfuzosin Str)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.